For research use only. Not for human or veterinary use. Supplied as a lyophilized powder for laboratory research.
The CJC-1295 with DAC vs without DAC question comes down to one chemical addition. CJC-1295, as defined in its 2005 discovery paper, is a tetrasubstituted form of human growth hormone-releasing factor hGRF(1-29) with an added Nε-3-maleimidopropionamide lysine at the C terminus [1]. That reactive group, often called the drug affinity complex (DAC), bonds to the free thiol on Cys34 of serum albumin, which extended the peptide’s presence in rat plasma beyond 72 hours [1]. “CJC-1295 without DAC” is the market name for the substituted GRF(1-29) peptide without that reactive lysine. It is also sold as “modified GRF(1-29)”.
What is CJC-1295?
CJC-1295 is a GHRH (growth hormone-releasing hormone) analog. In the discovery work [1]:
- Three maleimido derivatives of hGRF(1-29) were made; their albumin conjugates showed improved stability against the enzyme dipeptidyl peptidase-IV (DPP-IV) and stayed bioactive in a rat pituitary-cell GH secretion assay.
- The lead compound, CJC-1295, gave a 4-fold increase in GH area under the curve over 2 hours in rats compared with hGRF(1-29).
- A CJC-1295-immunoreactive species appeared on the serum albumin band within 15 minutes and remained in circulation beyond 24 hours.
CJC-1295 with DAC vs without DAC: side by side
| CJC-1295 with DAC | CJC-1295 without DAC (modified GRF 1-29) | |
|---|---|---|
| Core peptide | Tetrasubstituted hGRF(1-29) [1] | Substituted GRF(1-29) (market definition) |
| Reactive lysine (DAC) | Present: Nε-3-maleimidopropionamide lysine [1] | Absent |
| Albumin binding | Covalent, at Cys34 [1] | Not designed to bind albumin |
| Reported persistence | In rat plasma beyond 72 h [1] | No comparable peer-reviewed pharmacokinetic study was found under this name |
| PubChem | CID 91971820, C₁₆₅H₂₆₉N₄₇O₄₆, ~3647 g/mol (the DAC form) | No single verified record; check the lot certificate |
CJC-1295 research: what the literature covers
- The 2005 rat study established the albumin-conjugation design and the GH secretion response in rat pituitary cells [1].
- Direct peer-reviewed literature on the without-DAC form is thin, which is why most “no DAC” information online is extrapolated. Use the certificate’s formula and molecular weight as the definitive identifier for a given lot.
Regulatory status
FDA lists CJC-1295 in Category 2 of bulk drug substances nominated for compounding that may present significant safety risks [2]. It is not FDA-approved for any use.
Frequently asked questions
The DAC form carries a maleimido lysine that bonds covalently to serum albumin, greatly extending its persistence in plasma; the without-DAC form lacks that group [1].
Drug affinity complex: the Nε-3-maleimidopropionamide lysine that binds albumin at Cys34 [1].
In the 2005 discovery study, the albumin-bound DAC form remained in rat plasma beyond 72 hours [1]. No comparable peer-reviewed figure was found for the without-DAC form.
They are market names for the same concept: substituted GRF(1-29) without the albumin-binding lysine. Confirm identity from the lot certificate.
Research materials and certificates
- CJC-1295 (without DAC) · Ipamorelin + CJC-1295 Combo · COA Library
- Related: Ipamorelin Research · How to Read a Peptide COA
References
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-1286. PMID: 15817669
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Content current as of 04/22/2026. fda.gov
Research-use-only disclaimer: All products from My Freedom Peptides are supplied as a lyophilized powder for laboratory research. They are for research use only and not for human or veterinary use. My Freedom Peptides LLC is a chemical supplier. It is not a 503A compounding pharmacy or a 503B outsourcing facility. These statements have not been evaluated by the Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease.
